MONTPELLIER, France, June 23, 2016 (GLOBE NEWSWIRE) -- MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, today announced six new sales of its ROSA® Brain robot. Of the six robots, two were sold in the United States, two in China, one in England and one in France.
Details of these latest sales follow:
One ROSA® Brain was sold to the University of Minnesota Medical Center (Minneapolis, Minnesota), which offers adults and children some of the most advanced programs to treat disorders of the central nervous system, particularly epilepsy.
A second robot was sold to the Children’s National Health System (Washington, DC), a pediatric center of national and international renown for the treatment of disorders of the central nervous system. It also ranks among the ten best American pediatric hospitals for 2016, according to U.S. News & World Report.
Two additional sales of the robot were made in China, a dynamic market in Asia, representing a strong potential for development for Medtech. With these two new sales, Medtech now has 11 ROSA® Brain robots in China.
In England, a robot was sold to the Royal Hallamshire Hospital (Sheffield, South Yorkshire), a well-known specialist center offering a complete range of services in the field of neuroscience to treat disorders of the central nervous system.
A ROSA® Brain robot was sold to Kremlin-Bicêtre Hospital (Paris, Ile-de-France), which is part of a large group of public hospitals in Paris. This hospital center is particularly well-known for its neurology and neurosurgery departments. It was ranked by Le Point magazine as being among the 25 best French hospitals for patient care in that area.
Bertin Nahum, President and Founder of Medtech, said, “We are delighted with the steady progress in the number of ROSA® robots installed throughout the world, expanding patient access to the benefits of minimally invasive robotic procedures. These six new sales are the result of our strategic investments and focus on developing a broad global pipeline of potential new orders in this highly-promising, growing market.”
Sales for Q4 2016 to be released on Tuesday, July 5, 2016
Annual revenue (July 1, 2015 to June 30, 2016) to be released on Tuesday July 12, 2016
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA®, an innovative technological device devoted to brain surgery procedures. ROSA® has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA® Spine, a robotic-assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA® Spine, a robotic-assistive device for minimally invasive surgery of the spine.
CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel : +33 (0)4 67 10 77 40 INVESTORS Corinne Puissant Tel : +33 (0)1 53 67 36 77 email@example.com PRESS Alexandra Prisa (EU) Tel. : +33(0)1 53 67 36 90 firstname.lastname@example.org Joanna Zimmerman (US) Tel : +1 646-536-7006 email@example.com